Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Duchenne Muscular Dystrophy (DMD) Treatment Market Highlighting Regional Revenue Share Dominance During 2018-2026 on February 19, 2019 at 4:39 am
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused due to alteration in gene sequence coding for dystrophin protein, w... […]
- Single CRISPR treatment can safely and stably correct genetic disease on February 18, 2019 at 10:54 am
Genetic edits and protein restoration in mouse models of Duchenne muscular dystrophy remain viable one year after single CRISPR treatment Researchers at Duke University have shown that a single system... […]
- DMD: Single CRISPR treatment provides long-term benefits in mice on February 18, 2019 at 10:14 am
Researchers have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular dystrophy (DMD) -- for more than a y... […]
- Single CRISPR treatment provides long-term benefits in mice on February 18, 2019 at 8:05 am
DURHAM, N.C. -- Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular d... […]
- CRISPR corrects DMD in mice for a year in Sarepta-supported study on February 18, 2019 at 8:00 am
In 2017, Duchenne muscular dystrophy drug maker Sarepta signed a deal with Duke University to research potential cures for the disease using the gene-editing system CRISPR. Now the Duke lab at the cen... […]
- New breakthroughs for muscular dystrophy research on February 15, 2019 at 6:45 am
One step along the chain Vidal-Gadea's team examined was the amount of calcium released in the muscles of those battling Duchenne muscular dystrophy. "There is a build-up of calcium that is ... […]
- PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy on February 13, 2019 at 5:00 am
SOUTH PLAINFIELD, N.J., Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. PTCT, +1.74% today announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy. The ... […]
- URMC Designated as a Duchenne Care Center on February 11, 2019 at 12:14 pm
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization dedicated to advancing care and research for patients with Duchenne muscular dystrophy, has named the University of Rochester Medical ... […]
- Parent Project Muscular Dystrophy Designates University of Rochester Medical Center as a Certified Duchenne Care Center on February 11, 2019 at 7:23 am
HACKENSACK, N.J., Feb. 11, 2019 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), named the University ... […]
- A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy on February 7, 2019 at 9:47 am
Sarepta Therapeutics (ticker: SRPT) has solidified its position as the leader in the development of a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial re... […]
via Bing News